Three Motley Fool contributors believe they've identified dividend stocks to buy in September that fall into the latter ...

ABBV's expanding neuroscience portfolio, led by Botox, Vraylar and new launches like Vyalev, continues to fuel top-line ...

Parkinson's drugs market with our report, analyzing trends, revenue projections, and CAGRs from 2024 to 2030. Segmented by ...

The global Wearable Injectors Market, valued at US$10.2 billion in 2024, stood at US$11.33 billion in 2025 and is projected ...

A licensing deal worth at least $200 million will give Novartis access to a preclinical RNA medicine designed to combat ...

与此同时，艾伯维另一核心资产Emraclidine（CVL-231）作为一款高选择性毒蕈碱M4受体正变构调节剂（PAM），曾被视为下一代“best-in-class”抗精神病药物的有力竞争者。早期Ib期研究结果令人鼓舞，显示出良好的疗效、安全性和独特 ...

根据近期达成的合作协议，舶望制药将授予诺华两款处于发现阶段的下一代siRNA分子（针对重度高甘油三酯血症及混合性血脂异常）的中国境外许可权、一款正在中美两地开展II期临床的 BW-00112（ANGPTL3 siRNA） ...

​近日，艾伯维宣布将以最高12亿美元的价格收购Gilgamesh ...

AbbVie Inc. ( NYSE: ABBV) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Great. Thanks for joining us, everybody. I'm Terence Flynn, Morgan Stanley's U.S.

The British government said it withdrew the envoy after newly revealed emails showed the depth of his relationship with Jeffrey Epstein. By Mark Landler Ukrainian and European officials say President ...